…presenting with acute coronary syndrome (ACS) and confirmed by angiography or pathology. The Academic Research Consortium framework additionally distinguishes definite, probable, and possible stent thrombosis…

…through intimal thickening. DES release antiproliferative and anti inflammatory agents from the stent surface and have substantially reduced this process compared with BMS. Neoatherosclerosis Neoatherosclerosis…

…stents (BMS) in response to restenosis caused principally by neointimal hyperplasia. Contemporary DES combine a metallic scaffold, a polymeric or polymer free drug delivery system…

… stent related risk; whether long term oral anticoagulation is required; tolerance of treatment during the initial months. Patients with HBR are the principal candidates for…

…MI: MI related to PCI. Type 4b MI: MI caused by stent thrombosis. Type 4c MI: MI associated with in stent restenosis. Type 5 MI:…

…to provide similar efficacy to higher doses while reducing bleeding risk. Low dose aspirin is also preferred in patients with intracoronary stents. In acute ACS…

…used in two principal settings: After ACS , whether managed medically or with revascularization. After elective PCI for CCS , particularly after stent implantation. In both situations…

…the system, compared with roughly 70–200 µm for gray scale IVUS. This allows detailed visualization of the lumen surface, fibrous cap thickness, thrombus, stent…

…The phenomenon occurs in approximately 2%–3% of PCI procedures overall. It is particularly associated with intervention on degenerated saphenous vein grafts (SVGs), rotational atherectomy…

…4a MI: Represents a periprocedural myocardial infarction associated with percutaneous coronary intervention (PCI). Type 4b MI: Denotes myocardial infarction related to stent thrombosis following PCI…